New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
15:29 EDTMNKDFDA approves Afrezza to treat diabetes
The U.S. Food and Drug Administration today approved Afrezza Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal, or within 20 minutes after starting a meal. Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease. Afrezza should not be used in patients with chronic lung disease, such as asthma or COPD because of this risk. The most common adverse reactions associated with Afrezza in clinical trials were hypoglycemia, cough, and throat pain or irritation. The FDA approved Afrezza with a Risk Evaluation and Mitigation Strategy, which consists of a communication plan to inform health care professionals about the serious risk of acute bronchospasm associated with Afrezza. The FDA is requiring the following post-marketing studies for Afrezza: a clinical trial to evaluate pharmacokinetics, safety and efficacy in pediatric patients; a clinical trial to evaluate the potential risk of pulmonary malignancy with Afrezza, which will also assess cardiovascular risk and the long-term effect of Afrezza on pulmonary function; two pharmacokinetic-pharmacodynamic euglycemic glucose-clamp clinical trials, one to characterize dose-response and one to characterize within-subject variability. Afrezza is manufactured by MannKind.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
08:53 EDTMNKDNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
06:05 EDTMNKDStocks with implied volatility movement; MNKD MRVL
Subscribe for More Information
February 27, 2015
10:32 EDTMNKDOptions with decreasing implied volatility
Subscribe for More Information
February 25, 2015
05:52 EDTMNKDStocks with implied volatility movement; MNKD NE
Stocks with implied volatility movement; MannKind (MNKD) 79, Noble Corp. (NE) 52 according to iVolatility.
February 24, 2015
16:48 EDTMNKDMannKind reports Q4 EPS (9c), consensus (9c)
Subscribe for More Information
February 23, 2015
15:06 EDTMNKDMannKind volatility increases into Q4 and outlook
MannKind February weekly call option implied volatility is at 103, March is at 63, April is at 60. May is at 55; compared to its 26-week average of 70 according to Track Data, suggests large near term price movement into the expected release into the expected release of Q4 result on February 24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use